PepGen appoints Caroline Godfrey, Ph.D. to the Company


BOSTON, July 22. 10, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of serious neuromuscular and neurological diseases, has today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen’s scientific co-founders, to its Scientific Advisory Board. As part of the appointment, Dr. Godfrey steps down from her role as Senior Vice President of Discovery at PepGen.

“We are delighted that Caroline will continue to contribute to the science of PepGen as part of our Scientific Advisory Board, and we look forward to benefiting from her experience and guidance in the years to come,” said James McArthur, Ph. D., Chairman and CEO of PepGen. “As we consolidate and expand PepGen’s operations in Boston, this appointment facilitates continuity of expertise as we strive to develop transformative treatments for neuromuscular and neurological diseases. Caroline is one of our scientific co-founders and was appointed as the first Managing Director of PepGen following the company’s spin-off from the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation. In this role, and in her subsequent role as Senior Vice President of Discovery, she was instrumental in founding the company, securing the company’s initial and Series A financing, and leading our early-stage discovery efforts. We are extremely grateful for all that Caroline has done for PepGen and look forward to her continued contributions.

Prior to founding PepGen, Dr. Godfrey was a postdoctoral researcher focused on developing new tools for nucleic acid delivery in neuromuscular disorders before becoming a project manager at the University of Oxford. Drawing on research conducted with Professor Matthew Wood and Dr Michael Gait, Dr Godfrey co-founded PepGen and served as the company’s first CEO. Since January 2021, Dr. Godfrey has focused on discovery research as Senior Vice President of Discovery for PepGen. Dr. Godfrey obtained her Ph.D. in Neuromuscular Diseases from University College London and obtained his BS in Genetics from the University of Sheffield.

“I am delighted to take on a new position on the Scientific Advisory Board of PepGen,” said Dr. Godfrey. “I feel very privileged to have had the opportunity to lead the PepGen team through the early stages of the company’s development and to have played a role in advancing our Enhanced Delivery Oligonucleotide (EDO) technology. ) from the laboratory to the clinic. I look forward to continuing this journey with PepGen as we strive to bring our EDO therapies to patients who are in desperate need of transformative treatment options. »

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of serious neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is based on more than a decade of research and development and harnesses cell-penetrating peptides to enhance the uptake and potency of conjugated oligonucleotide therapies. Using these EDO peptides, PepGen generates a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements can be identified by words such as “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “plans”, “aims”, “intends”. of, “may”, “plans”, “possible”, “potential”, “seeks”, “will”, “looks forward to” and variations of these words or similar expressions which are intended to identify forward-looking statements. Such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, but are not limited to, statements about our clinical and preclinical programs, product candidates, technology, business and clinical/preclinical strategies, and Dr. Godfrey’s expected contributions to the business in the future. .

All forward-looking statements contained in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ. materially and unfavorably from those stated. in or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, that we may not successfully complete our Phase 1 trial for EDO51 and preclinical studies of other product candidates and obtain required pre-market approval; our product candidates may not be effective; there may be delays in regulatory approval or changes in the regulatory framework that are beyond our control; our estimate of addressable markets for our product candidates may be inaccurate; we may not raise required additional funds on a timely basis; more effective competitors or more effective competitive treatment may emerge; we may become involved in litigation regarding the use of our intellectual property essential to our success; we may not be able to attract and retain key employees and qualified personnel; results from previous studies may not be predictive of results from later studies; and we depend on third parties for some or all aspects of our product manufacturing, research, and preclinical and clinical testing. Additional risks regarding PepGen’s programs and operations are described in its registration statement on Form S-1, which is filed with the SEC, and in its most recent quarterly report on Form 10-Q on file with the SEC. . PepGen expressly disclaims any obligation to update forward-looking statements, except as required by law.

Contact Investor
Laurence Watts
Gilmartin Group
[email protected]

Media Contact
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
[email protected]


Comments are closed.